FTC conditions for Amneal merger with Impax

30 April 2018

The US Federal Trade Commission will require generic drug marketers privately-held Amneal Pharmaceuticals and Impax Laboratories (Nasdaq: IPXL) to divest Impax’ rights and assets for 10 products to three other companies, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition of an equity share in Impax, announced last October, likely would be anticompetitive.

According to the complaint, without a remedy, the acquisition would likely harm future competition in US markets for these seven generic products:

aspirin and dipyridamole extended-release capsules, an antiplatelet therapy used to reduce the risk of stroke;
azelastine nasal spray, a treatment for seasonal allergies;
diclofenac sodium and misoprostol delayed release tablets, a pain relief treatment that minimizes gastrointestinal side effects;
erythromycin tablets, an antibiotic;
fluocinonide-E cream, a topical corticosteroid used to reduce swelling, redness, itching, and allergic reactions;
methylphenidate hydrochloride extended release tablets, a central nervous system stimulant used to treat attention-deficit disorder and attention-deficit/hyperactivity disorder; and
olopatadine hydrochloride nasal spray, a treatment for seasonal allergies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK